Cargando…

The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth

Little is known about how specific individual viral lineages replicating systemically during acute Human Immunodeficiency Virus or Simian Immunodeficiency Virus (HIV/SIV) infection persist into chronic infection. In this study, we use molecularly barcoded SIV (SIVmac239M) to track distinct viral lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Moriarty, Ryan V., Golfinos, Athena E., Gellerup, Dane D., Schweigert, Hannah, Mathiaparanam, Jaffna, Balgeman, Alexis J., Weiler, Andrea M., Friedrich, Thomas C., Keele, Brandon F., Davenport, Miles P., Venturi, Vanessa, O’Connor, Shelby L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639003/
https://www.ncbi.nlm.nih.gov/pubmed/34855793
http://dx.doi.org/10.1371/journal.pone.0260010
_version_ 1784609060489789440
author Moriarty, Ryan V.
Golfinos, Athena E.
Gellerup, Dane D.
Schweigert, Hannah
Mathiaparanam, Jaffna
Balgeman, Alexis J.
Weiler, Andrea M.
Friedrich, Thomas C.
Keele, Brandon F.
Davenport, Miles P.
Venturi, Vanessa
O’Connor, Shelby L.
author_facet Moriarty, Ryan V.
Golfinos, Athena E.
Gellerup, Dane D.
Schweigert, Hannah
Mathiaparanam, Jaffna
Balgeman, Alexis J.
Weiler, Andrea M.
Friedrich, Thomas C.
Keele, Brandon F.
Davenport, Miles P.
Venturi, Vanessa
O’Connor, Shelby L.
author_sort Moriarty, Ryan V.
collection PubMed
description Little is known about how specific individual viral lineages replicating systemically during acute Human Immunodeficiency Virus or Simian Immunodeficiency Virus (HIV/SIV) infection persist into chronic infection. In this study, we use molecularly barcoded SIV (SIVmac239M) to track distinct viral lineages for 12 weeks after intravenous (IV) or intrarectal (IR) challenge in macaques. Two Mafa-A1*063+ cynomolgus macaques (Macaca fascicularis, CM) were challenged IV, and two Mamu-A1*001+ rhesus macaques (Macaca mulatta, RM) were challenged IR with 200,000 Infectious Units (IU) of SIVmac239M. We sequenced the molecular barcode of SIVmac239M from all animals over the 12 weeks of the study to characterize the diversity and persistence of virus lineages. During the first three weeks post-infection, we found ~70–560 times more unique viral lineages circulating in the animals challenged IV compared to those challenged IR, which is consistent with the hypothesis that the challenge route is the primary driver restricting the transmission of individual viral lineages. We also characterized the sequences of T cell epitopes targeted during acute SIV infection, and found that the emergence of escape variants in acutely targeted epitopes can occur on multiple virus templates simultaneously, but that elimination of some of these templates is likely a consequence of additional host factors. These data imply that virus lineages present during acute infection can still be eliminated from the systemic virus population even after initial selection.
format Online
Article
Text
id pubmed-8639003
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-86390032021-12-03 The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth Moriarty, Ryan V. Golfinos, Athena E. Gellerup, Dane D. Schweigert, Hannah Mathiaparanam, Jaffna Balgeman, Alexis J. Weiler, Andrea M. Friedrich, Thomas C. Keele, Brandon F. Davenport, Miles P. Venturi, Vanessa O’Connor, Shelby L. PLoS One Research Article Little is known about how specific individual viral lineages replicating systemically during acute Human Immunodeficiency Virus or Simian Immunodeficiency Virus (HIV/SIV) infection persist into chronic infection. In this study, we use molecularly barcoded SIV (SIVmac239M) to track distinct viral lineages for 12 weeks after intravenous (IV) or intrarectal (IR) challenge in macaques. Two Mafa-A1*063+ cynomolgus macaques (Macaca fascicularis, CM) were challenged IV, and two Mamu-A1*001+ rhesus macaques (Macaca mulatta, RM) were challenged IR with 200,000 Infectious Units (IU) of SIVmac239M. We sequenced the molecular barcode of SIVmac239M from all animals over the 12 weeks of the study to characterize the diversity and persistence of virus lineages. During the first three weeks post-infection, we found ~70–560 times more unique viral lineages circulating in the animals challenged IV compared to those challenged IR, which is consistent with the hypothesis that the challenge route is the primary driver restricting the transmission of individual viral lineages. We also characterized the sequences of T cell epitopes targeted during acute SIV infection, and found that the emergence of escape variants in acutely targeted epitopes can occur on multiple virus templates simultaneously, but that elimination of some of these templates is likely a consequence of additional host factors. These data imply that virus lineages present during acute infection can still be eliminated from the systemic virus population even after initial selection. Public Library of Science 2021-12-02 /pmc/articles/PMC8639003/ /pubmed/34855793 http://dx.doi.org/10.1371/journal.pone.0260010 Text en © 2021 Moriarty et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Moriarty, Ryan V.
Golfinos, Athena E.
Gellerup, Dane D.
Schweigert, Hannah
Mathiaparanam, Jaffna
Balgeman, Alexis J.
Weiler, Andrea M.
Friedrich, Thomas C.
Keele, Brandon F.
Davenport, Miles P.
Venturi, Vanessa
O’Connor, Shelby L.
The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth
title The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth
title_full The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth
title_fullStr The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth
title_full_unstemmed The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth
title_short The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth
title_sort mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639003/
https://www.ncbi.nlm.nih.gov/pubmed/34855793
http://dx.doi.org/10.1371/journal.pone.0260010
work_keys_str_mv AT moriartyryanv themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT golfinosathenae themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT gellerupdaned themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT schweigerthannah themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT mathiaparanamjaffna themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT balgemanalexisj themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT weilerandream themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT friedrichthomasc themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT keelebrandonf themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT davenportmilesp themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT venturivanessa themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT oconnorshelbyl themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT moriartyryanv mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT golfinosathenae mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT gellerupdaned mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT schweigerthannah mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT mathiaparanamjaffna mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT balgemanalexisj mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT weilerandream mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT friedrichthomasc mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT keelebrandonf mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT davenportmilesp mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT venturivanessa mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth
AT oconnorshelbyl mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth